Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

Mov Disord. 2022 Nov;37(11):2315-2317. doi: 10.1002/mds.29212. Epub 2022 Sep 23.

Authors

Claire Pauly^{1

2}, Enrico Glaab¹, Maxime Hansen^{2

3}, Camille Martin-Gallausiaux¹, Mirko Ledda¹, Tainá M Marques¹, Paul Wilmes^{1

4}, Rejko Krüger^{1

2

3

5}, Nico J Diederich⁵; NCER-PD Consortium

Affiliations

¹ Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
² Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
³ Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg.
⁴ Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
⁵ Department of Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

PMID: 36148927
DOI: 10.1002/mds.29212

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
COVID-19*
Disease Progression
Humans
Inflammation
Pandemics
Parkinson Disease* / epidemiology

Substances

Biomarkers